Not Yet Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT06871527

Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer

Fruquintinib Combined With Tislelizumab and FOLFOX as First-Line Treatment For Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-center, Open-label, Phase Ib/II Clinical Study

Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University

Conditions Fruquintinib GEJ Adenocarcinoma Gastric (Stomach) Cancer Gastric Adenocarcinoma PD-1 Inhibitor Tislelizumab

Interventions fruquintinib + tislelizumab + FOLFOX

Updated 1 time since 2025 Last updated: Mar 11, 2025 Started: Mar 1, 2025 Primary completion: Mar 30, 2028 Completion: Dec 31, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Fruquintinib and GEJ Adenocarcinoma and is currently actively recruiting participants. Sixth Affiliated Hospital, Sun Yat-sen University leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

1 version recorded

Not Yet Recruiting — PHASE1/PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sixth Affiliated Hospital, Sun Yat-sen University

Data source: Sixth Affiliated Hospital, Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China